Privileged structures: efficient chemical "navigators" toward unexplored biologically relevant chemical spaces.

In the search for new therapeutic agents for currently incurable diseases, attention has turned to traditionally "undruggable" targets, and collections of drug-like small molecules with high diversity and quality have become a prerequisite for new breakthroughs. To generate such collections, the diversity-oriented synthesis (DOS) strategy was developed, which aims to populate new chemical space with drug-like compounds containing a high degree of molecular diversity. The resulting DOS-derived libraries have been of great value for the discovery of various bioactive small molecules and therapeutic agents, and thus DOS has emerged as an essential tool in chemical biology and drug discovery. However, the key challenge has become how to design and synthesize drug-like small-molecule libraries with improved biological relevancy as well as maximum molecular diversity. This Perspective presents the development of privileged substructure-based DOS (pDOS), an efficient strategy for the construction of polyheterocyclic compound libraries with high biological relevancy. We envisioned the specific interaction of drug-like small molecules with certain biopolymers via the incorporation of privileged substructures into polyheterocyclic core skeletons. The importance of privileged substructures such as benzopyran, pyrimidine, and oxopiperazine in rigid skeletons was clearly demonstrated through the discovery of bioactive small molecules and the subsequent identification of appropriate target biomolecule using a method called "fluorescence difference in two-dimensional gel electrophoresis". Focusing on examples of pDOS-derived bioactive compounds with exceptional specificity, we discuss the capability of privileged structures to serve as chemical "navigators" toward biologically relevant chemical spaces. We also provide an outlook on chemical biology research and drug discovery using biologically relevant compound libraries constructed by pDOS, biology-oriented synthesis, or natural product-inspired DOS.

[1]  David R Spring,et al.  Is synthesis the main hurdle for the generation of diversity in compound libraries for screening? , 2009, Expert opinion on drug discovery.

[2]  S. Park,et al.  Novel application of Leuckart-Wallach reaction for synthesis of tetrahydro-1,4-benzodiazepin-5-ones library. , 2007, Chemical communications.

[3]  A. Hopkins,et al.  Navigating chemical space for biology and medicine , 2004, Nature.

[4]  Wolfgang H. B. Sauer,et al.  Molecular Shape Diversity of Combinatorial Libraries: A Prerequisite for Broad Bioactivity , 2003, J. Chem. Inf. Comput. Sci..

[5]  S. Park,et al.  Solid-phase parallel synthesis of natural product-like diaza-bridged heterocycles through Pictet-Spengler intramolecular cyclization. , 2006, Journal of combinatorial chemistry.

[6]  Jongmin Park,et al.  Development of a Benzopyran‐Containing Androgen Receptor Antagonist to Treat Antiandrogen‐Resistant Prostate Cancer , 2010, ChemMedChem.

[7]  David R Spring,et al.  A strategy for the diversity-oriented synthesis of macrocyclic scaffolds using multidimensional coupling. , 2013, Nature chemistry.

[8]  Brett M. Ibbeson,et al.  Diversity-oriented synthesis as a tool for identifying new modulators of mitosis , 2014, Nature Communications.

[9]  R. Mrak,et al.  Microglia and neuroinflammation: a pathological perspective , 2004 .

[10]  D. Swinney,et al.  How were new medicines discovered? , 2011, Nature Reviews Drug Discovery.

[11]  J. Vederas,et al.  Drug Discovery and Natural Products: End of an Era or an Endless Frontier? , 2009, Science.

[12]  X. García‐Mera,et al.  Pyrimidine derivatives as potent and selective A3 adenosine receptor antagonists. , 2011, Journal of medicinal chemistry.

[13]  K. Tracey,et al.  Targeting HMGB1 in inflammation. , 2010, Biochimica et biophysica acta.

[14]  Stuart L. Schreiber,et al.  Stereoselective Synthesis of over Two Million Compounds Having Structural Features Both Reminiscent of Natural Products and Compatible with Miniaturized Cell-Based Assays , 1998 .

[15]  K. Tracey,et al.  HMG-1 as a late mediator of endotoxin lethality in mice. , 1999, Science.

[16]  Stefan Wetzel,et al.  Biology-oriented synthesis. , 2011, Angewandte Chemie.

[17]  Stuart L Schreiber,et al.  A planning strategy for diversity-oriented synthesis. , 2004, Angewandte Chemie.

[18]  Y. Jo,et al.  Antidiabetic and antiobesity effects of Ampkinone (6f), a novel small molecule activator of AMP-activated protein kinase. , 2010, Journal of medicinal chemistry.

[19]  Stuart L Schreiber,et al.  Skeletal diversity via a branched pathway: efficient synthesis of 29 400 discrete, polycyclic compounds and their arraying into stock solutions. , 2002, Journal of the American Chemical Society.

[20]  David R Spring,et al.  Diversity-oriented synthesis as a tool for the discovery of novel biologically active small molecules. , 2010, Nature communications.

[21]  Adam Nelson,et al.  Natural products as an inspiration in the diversity-oriented synthesis of bioactive compound libraries , 2008, Natural product reports.

[22]  B. Ho,et al.  Inhibitors of monoamine oxidase. Influence of methyl substitution on the inhibitory activity of beta-carbolines. , 1968, Journal of pharmaceutical sciences.

[23]  Craig M. Crews,et al.  Targeting the undruggable proteome: the small molecules of my dreams. , 2010, Chemistry & biology.

[24]  J. Casida,et al.  Combinatorial synthesis of novel and potent inhibitors of NADH:ubiquinone oxidoreductase. , 2000, Chemistry & biology.

[25]  Jongmin Park,et al.  Discovery and target identification of an antiproliferative agent in live cells using fluorescence difference in two-dimensional gel electrophoresis. , 2012, Angewandte Chemie.

[26]  J. Mason,et al.  New 4-point pharmacophore method for molecular similarity and diversity applications: overview of the method and applications, including a novel approach to the design of combinatorial libraries containing privileged substructures. , 1999, Journal of medicinal chemistry.

[27]  Michelle R. Arkin,et al.  Small-molecule inhibitors of protein–protein interactions: progressing towards the dream , 2004, Nature Reviews Drug Discovery.

[28]  M. Breuning,et al.  Elevated TGFβ–Smad signalling in experimental Pkd1 models and human patients with polycystic kidney disease , 2010, The Journal of pathology.

[29]  David R Spring,et al.  Diversity-oriented synthesis: producing chemical tools for dissecting biology. , 2012, Chemical Society reviews.

[30]  Jérôme Hert,et al.  Quantifying Biogenic Bias in Screening Libraries , 2009, Nature chemical biology.

[31]  R. Hicklin,et al.  Synthesis of complex and diverse compounds through ring distortion of abietic acid. , 2014, Angewandte Chemie.

[32]  D C Swinney,et al.  Phenotypic vs. Target‐Based Drug Discovery for First‐in‐Class Medicines , 2013, Clinical pharmacology and therapeutics.

[33]  R. Hicklin,et al.  A ring-distortion strategy to construct stereochemically complex and structurally diverse compounds from natural products. , 2013, Nature chemistry.

[34]  C. Avendaño,et al.  Pictet Spengler-type reactions in 3-arylmethylpiperazine-2,5-diones. Synthesis of pyrazinotetrahydroisoquinolines , 2004 .

[35]  L. Allen Stem cells. , 2003, The New England journal of medicine.

[36]  M. Block,et al.  Microglia and inflammation-mediated neurodegeneration: Multiple triggers with a common mechanism , 2005, Progress in Neurobiology.

[37]  Seung Bum Park,et al.  A design strategy for drug-like polyheterocycles with privileged substructures for discovery of specific small-molecule modulators. , 2011, Chemical communications.

[38]  Adam Nelson,et al.  Synthesis of Natural-Product-Like Molecules with Over Eighty Distinct Scaffolds** , 2008, Angewandte Chemie.

[39]  W. Guida,et al.  The art and practice of structure‐based drug design: A molecular modeling perspective , 1996, Medicinal research reviews.

[40]  Stuart L. Schreiber,et al.  The small-molecule approach to biology , 2003 .

[41]  Kevin J. Tracey,et al.  High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal , 2005, Nature Reviews Immunology.

[42]  Seung Bum Park,et al.  Diversity-oriented synthesis of privileged benzopyranyl heterocycles from s-cis-enones. , 2008, The Journal of organic chemistry.

[43]  B. Stockwell Chemical genetics: ligand-based discovery of gene function , 2000, Nature Reviews Genetics.

[44]  N. Gray,et al.  Discovery of EGFR selective 4,6-disubstituted pyrimidines from a combinatorial kinase-directed heterocycle library. , 2006, Journal of the American Chemical Society.

[45]  H. Mario Geysen,et al.  A guide to drug discovery: Combinatorial compound libraries for drug discovery: an ongoing challenge , 2003, Nature Reviews Drug Discovery.

[46]  K. Suk,et al.  A small molecule binding HMGB1 and HMGB2 inhibits microglia-mediated neuroinflammation. , 2014, Nature chemical biology.

[47]  A. Myers,et al.  A solid-supported, enantioselective synthesis suitable for the rapid preparation of large numbers of diverse structural analogues of (-)-saframycin A. , 2002, Journal of the American Chemical Society.

[48]  R A Houghten,et al.  Parallel array and mixture-based synthetic combinatorial chemistry: tools for the next millennium. , 2000, Annual review of pharmacology and toxicology.

[49]  David J Newman,et al.  Natural products as leads to potential drugs: an old process or the new hope for drug discovery? , 2008, Journal of medicinal chemistry.

[50]  Y. Feng,et al.  Use of biomimetic diversity-oriented synthesis to discover galanthamine-like molecules with biological properties beyond those of the natural product. , 2001, Journal of the American Chemical Society.

[51]  Anthony E. Boitano,et al.  Chemical control of stem cell fate and developmental potential. , 2011, Angewandte Chemie.

[52]  Renato A. Bauer,et al.  Biomimetic diversity-oriented synthesis of benzannulated medium rings via ring expansion , 2012, Nature chemical biology.

[53]  S. Danishefsky,et al.  Total synthesis of cribrostatin IV: fine-tuning the character of an amide bond by remote control. , 2005, Journal of the American Chemical Society.

[54]  Tjelvar S. G. Olsson,et al.  The thermodynamics of protein-ligand interaction and solvation: insights for ligand design. , 2008, Journal of molecular biology.

[55]  Lorenzo Moroni,et al.  Differential Response of Adult and Embryonic Mesenchymal Progenitor Cells to Mechanical Compression in Hydrogels , 2007, Stem cells.

[56]  Peter G. Schultz,et al.  A Stem Cell–Based Approach to Cartilage Repair , 2012, Science.

[57]  Helen J. Mitchell,et al.  Natural Product-like Combinatorial Libraries Based on Privileged Structures. 1. General Principles and Solid-Phase Synthesis of Benzopyrans , 2000 .

[58]  J. Choi,et al.  Phenotypic screening to identify small-molecule enhancers for glucose uptake: target identification and rational optimization of their efficacy. , 2014, Angewandte Chemie.

[59]  L. Ulloa,et al.  High-mobility group box 1 (HMGB1) protein: friend and foe. , 2006, Cytokine & growth factor reviews.

[60]  Y. Chung,et al.  Preparation of pilot library with tetrahydro-β-carboline alkaloid core skeleton using tandem intramolecular Pictet–Spengler cyclization , 2006 .

[61]  H. Beug,et al.  TGFβ signaling is necessary for carcinoma cell invasiveness and metastasis , 1998, Current Biology.

[62]  Alan L Harvey,et al.  Natural products in drug discovery. , 2008, Drug discovery today.

[63]  L. Sternbach The benzodiazepine story. , 1983, Journal of psychoactive drugs.

[64]  Dong-Sup Lee,et al.  A potent small-molecule inducer of chondrogenic differentiation of human bone marrow-derived mesenchymal stem cells , 2012 .

[65]  S. Masamune,et al.  Total Synthesis of the L-Hexoses , 1983, Science.

[66]  A. Mantalaris,et al.  TGF-β3: A potential biological therapy for enhancing chondrogenesis , 2009 .

[67]  Lakshmi B. Akella,et al.  Diversity-Oriented Synthesis Approach to Macrocycles via Oxidative Ring Expansion , 2012, Nature chemical biology.

[68]  A. Coyle,et al.  HMGB1 and RAGE in inflammation and cancer. , 2010, Annual review of immunology.

[69]  Stefan Wetzel,et al.  Charting, navigating, and populating natural product chemical space for drug discovery. , 2012, Journal of medicinal chemistry.

[70]  Sangmi Oh,et al.  Construction of a polyheterocyclic benzopyran library with diverse core skeletons through diversity-oriented synthesis pathway. , 2010, Journal of combinatorial chemistry.

[71]  S. Gabriel,et al.  Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. , 2008, Arthritis and rheumatism.

[72]  R. Morphy Selectively nonselective kinase inhibition: striking the right balance. , 2010, Journal of medicinal chemistry.

[73]  Stuart L. Schreiber,et al.  Organic chemistry: Molecular diversity by design , 2009, Nature.

[74]  N. Mohamed,et al.  Derivatized oxopiperazine rings from amino acids , 1997 .

[75]  T. Tung,et al.  Privileged substructure-based diversity-oriented synthesis pathway for diverse pyrimidine-embedded polyheterocycles. , 2013, Organic letters.

[76]  M. Pittenger,et al.  Multilineage potential of adult human mesenchymal stem cells. , 1999, Science.

[77]  S. Schreiber PERSPECTIVE: THE SMALL-MOLECULE APPROACH TO BIOLOGYChemical genetics and diversity-oriented organic synthesis make possible the systematic exploration of biology , 2003 .

[78]  M. Block,et al.  Microglia-mediated neurotoxicity: uncovering the molecular mechanisms , 2007, Nature Reviews Neuroscience.

[79]  Derek S. Tan,et al.  Diversity-oriented synthesis: exploring the intersections between chemistry and biology , 2005, Nature chemical biology.

[80]  D. Newman,et al.  Natural products as sources of new drugs over the last 25 years. , 2007, Journal of natural products.

[81]  S. Ōmura,et al.  Generation of anti-trypanosomal agents through concise synthesis and structural diversification of sesquiterpene analogues. , 2011, Journal of the American Chemical Society.

[82]  Sun Wook Cho,et al.  Discovery of a novel benzopyranyl compound as a potent in vitro and in vivo osteogenic agent , 2011 .

[83]  Jongmin Park,et al.  Development of a cy3-labeled glucose bioprobe and its application in bioimaging and screening for anticancer agents. , 2007, Angewandte Chemie.

[84]  R. Strausberg,et al.  From Knowing to Controlling: A Path from Genomics to Drugs Using Small Molecule Probes , 2003, Science.

[85]  Tim Hardingham,et al.  Tissue engineering: chondrocytes and cartilage , 2002, Arthritis research.

[86]  Kyuho Han,et al.  The imidazopyridine derivative JK184 reveals dual roles for microtubules in Hedgehog signaling. , 2009, Angewandte Chemie.

[87]  S. Wetzel,et al.  Biology-inspired synthesis of compound libraries , 2008, Cellular and Molecular Life Sciences.

[88]  H. Waldmann,et al.  Biology-oriented synthesis of stereochemically diverse natural-product-derived compound collections by iterative allylations on a solid support. , 2007, Chemistry.

[89]  Sanghee Lee,et al.  Discovery of novel benzopyranyl tetracycles that act as inhibitors of osteoclastogenesis induced by receptor activator of NF-κB ligand. , 2010, Journal of medicinal chemistry.

[90]  P. Clemons,et al.  Target identification and mechanism of action in chemical biology and drug discovery. , 2013, Nature chemical biology.

[91]  B. E. Evans,et al.  Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. , 1988, Journal of Medicinal Chemistry.

[92]  L. Banaszynski,et al.  A Rapid, Reversible, and Tunable Method to Regulate Protein Function in Living Cells Using Synthetic Small Molecules , 2006, Cell.

[93]  S. Schreiber,et al.  Target-oriented and diversity-oriented organic synthesis in drug discovery. , 2000, Science.

[94]  Douglas A. Horton,et al.  The combinatorial synthesis of bicyclic privileged structures or privileged substructures. , 2003, Chemical reviews.

[95]  Herbert Waldmann,et al.  Exploring and exploiting biologically relevant chemical space. , 2011, Current drug targets.

[96]  J. Baldwin,et al.  A new and efficient method for o-quinone methide intermediate generation: application to the biomimetic synthesis of the benzopyran derived natural products (+/-)-lucidene and (+/-)-alboatrin. , 2005, Organic & biomolecular chemistry.